Clinical cardiac MRI protocols can be insensitive to secondary cardiomyopathy induced myocardium thickening and altered cardiac function. In this work, we demonstrate the feasibility of acquiring cardiac relaxivity contrast imaging (RCI) data, and specifically the RCI-parameter termed transverse relaxivity at tracer equilibrium (TRATE). TRATE has previously been shown to detect changes in cellular microstructure. RCI acquisition comprises of 1) pre-/post-contrast T1 maps using a MOLLI protocol, and 2) pre-/post-contrast T2* maps using a multi-gradient echo protocol. Robust changes in post contrast R2*, and the subsequent TRATE values, support the potential role of using RCI to study myocardial microstructure changes.